HRH4 and cancer: This has been well established in both animal models and cancer patients, where accumulation of Tregs in TDLNs and not in tumour is correlated with disease progression.51 In addition, treatment with a specific H4R agonist, JNJ2828610244, significantly increased the percentage of Tregs in TDLN of WT mice.